Longevity Biotech’s Precision Neuroscience Platform allows for the interrogation of the ‘fitness’ of an individual’s immune system by measuring specific biomarkers as well as specific immune cell phenotyping that are demonstrative of immune dysfunction. Longevity Biotech is actively defining novel patient populations based on the current state of an individual’s immune system, not simply by their genetic traits. By identifying individuals with immune dysfunction, Longevity Biotech identifies differences between closely related and hard-to-diagnose diseases, even across disease subtypes. Leveraging the Precision Neuroscience Platform, Longevity Biotech can group similar individuals into specific disease subtypes based on their biomarkers. Importantly, Longevity Biotech can conduct this analysis using a routine blood draw.
Longevity Biotech is focused on using the Precision Neuroscience Platform to identify patient populations that will uniquely benefit from Longevity Biotech’s product portfolio. To date, Longevity Biotech has identified different subsets of Parkinson’s disease patients with dysregulated immune systems.
Leveraging our Precision Neuroscience platform, Longevity Biotech is currently expanding to other related neurodegenerative diseases beyond Parkinson’s Disease. We work with partners to identify novel patient populations for their product candidates. If you are interested in partnering with Longevity Biotech, please contact us to learn more.
